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Abstract  
 
Defects in the astrocytic membrane protein MLC1, the adhesion molecule 
GlialCAM or the chloride channel ClC-2 underlie human leukoencephalopathies. 
Whereas GlialCAM binds ClC-2 and MLC1, and modifies ClC-2 currents in vitro, 
no functional connections between MLC1 and ClC-2 are known. Here we 
investigate this by generating loss-of-function Glialcam and Mlc1 mouse models 
manifesting myelin vacuolization. We find that ClC-2 is unnecessary for MLC1 
and GlialCAM localization in brain, whereas GlialCAM is important for targeting 
MLC1 and ClC-2 to specialized glial domains in vivo and for modifying ClC-2’s 
biophysical properties specifically in oligodendrocytes (OLs), the cells chiefly 
affected by vacuolization. Unexpectedly, MLC1 is crucial for proper localization 
of GlialCAM and ClC-2, and for changing ClC-2 currents. Our data unmask an 
unforeseen functional relationship between MLC1 and ClC-2 in vivo, which is 
probably mediated by GlialCAM, and suggest that ClC-2 participates in the 
pathogenesis of megalencephalic leukoencephalopathy with subcortical cysts. 
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Introduction  
 
Several forms of leukodystrophies, degenerative disorders affecting the white 
matter of the brain, are associated with vacuolization of myelin sheaths that 
enwrap axons of central neurons. A particular subentity of this disease, 
megalencephalic leukoencephalopathy with subcortical cysts (in short MLC), 
can be caused by mutations in either MLC11, encoding a protein predicted to 
span the plasma membrane eight times, or less frequently in GLIALCAM 2,3 
which encodes the adhesion molecule GlialCAM of the immunoglobulin 
superfamily4. MLC1 and GlialCAM bind each other, and this binding originally 
suggested GLIALCAM as a candidate gene for MLC2. GlialCAM was first 
identified as being downregulated in hepatic cancer (hence its original name 
HepaCAM5), but is predominantly expressed in glial cells6. GlialCAM co-
localizes with its binding partner MLC1 at astrocytic endfeet contacting blood 
vessels and at astrocyte-astrocyte contacts7. GlialCAM and MLC1 share this 
localization with the ClC-2 chloride channel8. In addition to other symptoms9, 
Clcn2-/- mice display leukodystrophy8, suggesting that ClC-2 deficiency might 
underlie human leukoencephalopathy. Screens for CLCN2 mutations in 
leukodystrophy patients were initially negative8,10, but a recent study identified 
CLCN2 mutations in a distinct form of leukoencephalopathy11. Clinical 
symptoms of either form of the disease include ataxia and sometimes spasticity. 
Based on a limited number of patients, CLCN2 leukodystrophy differs from MLC 
in the magnetic resonance imaging (MRI) pattern of affected brains11. By 
contrast, clinical and MRI features of patients with the MLC1 disease entity 
(mutations in MLC1) are virtually indistinguishable from those affected by 
MLC2A (GLIALCAM mutations on both alleles). The disease is more benign in 
patients with heterozygous GLIALCAM mutations in dominantly inherited 
MLC2B2. 
GlialCAM not only binds MLC1, but also ClC-212, a widely expressed Cl- 
channel activated by hyperpolarization and cell swelling13-15. ClC-2 is found in 
both neurons and glia. GlialCAM directs ClC-2 and MLC1 to cell-cell contacts in 
heterologous expression. This effect is abolished by several point mutations 
found in MLC2 patients3,7,12. GlialCAM drastically changes ClC-2 currents in 
various expression systems by increasing their amplitudes and almost 
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abolishing their inward rectification12. It thus appears possible that GlialCAM 
mutations cause leukodystrophy by mislocalizing ClC-2 and/or by affecting its 
currents. By contrast, no effects of MLC1 on ClC-2 function, localization, or 
abundance were found12,16. Thus, it remains unclear why patients with MLC1 
mutations have the same symptoms as patients with recessive GLIALCAM 
mutations, who, based on these cell culture data, would be expected to be more 
severely affected. 
To investigate the functional network of MLC1, GlialCAM, and ClC-2 in 
vivo and its role in leukodystrophy, we now generate mice lacking MLC1 or 
GlialCAM proteins (Mlc1-/- and Glialcam-/- mice, respectively), and Glialcamdn/dn 
knock-in mice harboring a dominant point mutation found in patients2,12. All 
three mouse lines develop progressive myelin vacuolization in the cerebellum. 
Loss of GlialCAM changes the localization and abundance of ClC-2 and MLC1, 
and surprisingly loss of MLC1 changes the localization of ClC-2 and GlialCAM. 
The linearization and enhancement of ClC-2 currents by GlialCAM that is known 
from heterologous expression is observed in OLs, but not in Bergmann glia 
(BG). Hence GlialCAM-dependent anchoring of ClC-2 to plasma membrane 
domains is not necessarily coupled with changes in ClC-2 current 
characteristics. Crosses between different Clcn2 and Glialcam models indicate 
that the pathology observed with loss of GlialCAM or MLC1 may be partially 
attributed to a secondary loss of ClC-2 function, but that the loss of either 
GlialCAM or MLC1 has additional pathogenic effects.  
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Results 
 
Mlc1 and Glialcam mouse models 
Exons 2 and 3 of the Mlc1 gene were deleted to generate Mlc1-/- mice 
(Supplementary Fig. 1a,b). Western blots confirmed the absence of the MLC1 
protein (Fig. 1a). A point mutation was inserted into the mouse Glialcam gene 
that changes G89 in the first immunoglobulin domain to serine (Supplementary 
Fig. 1c-e). This mutation (G89S) is found in MLC patients with dominant 
disease2. Exons 2-4 were flanked by loxP sites to generate GlialCAM KO 
(Glialcam-/-) mice by crossing GlialcamG89S,loxP (in the following called 
Glialcamdn) mice with deleter mice17 (Supplementary Fig. 1c,e). Glialcamdn 
mRNA was expressed at normal levels in brain (Fig. 1b). Western blots showed 
that the G89S mutation did not reduce GlialCAM levels (Fig. 1c,d) and that 
GlialCAM, although initially called HepaCAM, lacks significant expression in 
liver6 (Fig. 1a). As expected, GlialCAM was absent from Glialcam-/- brain. 
Mlc1-/-, Glialcam-/- and Glialcamdn/dn mice were viable and fertile. Like 
Clcn2-/- mice8, they lacked overt ataxia or spasticity as might have been 
expected from MLC patients with mutations in the MLC1 or GLIALCAM 
(HEPACAM) genes1,2.  
 
Interdependent protein expression of GlialCAM MLC1 and ClC-2 
We wondered whether the expression of ClC-2 and MLC1, both of which bind 
GlialCAM2,12, might be changed in the Glialcam mouse models. As myelin 
vacuolization is most pronounced in the cerebellum of Clcn2-/- mice8 and  in the 
present Glialcam and Mlc1 models (see below), we separately studied protein 
expression in the cerebellum and the rest of the brain. ClC-2 was reduced by 
~50% in Glialcam-/- and Glialcamdn/dn cerebella (Fig. 1c) but not in the remaining 
brain (Fig. 1d). MLC1 was strongly decreased in the whole brain of Glialcam-/- 
mice, whereas in Glialcamdn/dn mice, MLC1 was moderately decreased only in 
cerebellum (Fig. 1c,d). Although MLC1 reportedly binds GlialCAM, but not ClC-
22,12, ClC-2 was reduced in Mlc1-/- cerebellum (Fig. 1c) whereas GlialCAM 
appeared nearly unchanged (Fig. 1c,d). Agreeing with previous work12, 
GlialCAM and MLC1 were not reduced in Clcn2-/- brain and MLC1 appeared 
even somewhat increased in Clcn2-/- cerebellum (Fig. 1c,d).  
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Hence, GlialCAM stabilizes MLC1 and the G89S mutant partially retains 
this stabilizing effect. Both proteins stabilize ClC-2 in the cerebellum. However, 
ClC-2 is not required for the stability of either GlialCAM or MLC1. These 
stabilizing effects occur posttranscriptionally as qRT-PCR showed no changes 
in mRNA levels (Figure 1b). 
 
Mutually dependent localization of GlialCAM MLC1 and ClC-2 
Whereas GlialCAM directs ClC-2 and MLC1 to cell-cell junctions, MLC1 co-
transfection does not change the localization of either GlialCAM or ClC-27,12. 
We asked whether these in vitro results are relevant in vivo. We first focused on 
cerebellar Bergmann glia (BG) because their long, straight processes showed 
particularly prominent, overlapping labelling for ClC-2, MLC1 and GlialCAM 
(Fig. 2a). Moreover, the morphology of BG allows easy visualization of changes 
in subcellular localization. Whereas ClC-2 disruption had no detectable effect on 
GlialCAM and MLC1 in BG12 (Fig. 2a), ablation of GlialCAM strongly reduced 
the labelling for both ClC-2 and MLC1 and changed their localization (Fig. 2a,b). 
Rather than being concentrated along BG processes, both proteins showed 
faint diffuse staining in the molecular layer and in BG somata where a sizeable 
portion of immunoreactivity appeared intracellular (Fig. 2b).  
In Glialcamdn/dn mice, in which GlialCAM binding properties might be 
altered by the G89S mutation in the first extracellular Ig-domain2, GlialCAM 
antibodies did not label the straight BG processes, but still diffusely stained the 
molecular layer (Fig. 2a). Heterozygous Glialcam+/dn mice showed an 
intermediate phenotype with  MLC1 being diffusely labelled in the molecular 
layer and only small amounts remaining along BG processes (Fig. 2a). In both 
homo- and heterozygous Glialcamdn mice ClC-2 was retained in BG somata 
with ClC-2 extending further into BG processes in Glialcam+/dn mice (Fig. 2a).  
Agreeing with the Western blot analysis, overall labelling of ClC-2 was 
reduced in Mlc1-/- cerebella (Fig. 2a), and ClC-2 was retained in BG somata like 
in Glialcam-/- mice (Fig. 2a,b). GlialCAM immunolabelling was similarly diffuse in 
Mlc1-/- as in Glialcamdn/dn cerebellum.  
ClC-2, GlialCAM and MLC1 localization at astrocytic endfeet along blood 
vessels was reduced in Glialcam-/-, Glialcamdn/dn and Mlc1-/- mice (Fig. 3a). In 
contrast, the localization of the water channel aquaporin 4 and the K+-channel 
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Kir4.1 (KCNJ10), two proteins reported18 to reside in a complex with MLC1, 
were not changed in  Mlc1-/- and Glialcam-/- mice (Fig. 3b). 
In wild-type (WT) OLs ClC-2, GlialCAM and MLC1 clustered around their 
somata (Fig. 4), as previously described for ClC-2 and GlialCAM8,12. However, 
unlike ClC-2 and GlialCAM, MLC1 is apparently not expressed in OLs2,19,20. 
Because MLC1 was detected in neighbouring bona fide astrocytes (Fig. 4) the 
MLC1 staining at oligodendrocytic somata may stem from contact-forming 
astrocytic processes.  
In Glialcam-/-, Glialcamdn/dn and Mlc1-/- mice, ClC-2 no longer formed 
distinct clusters at the oligodendrocytic plasma membrane but showed faint 
diffuse, inhomogeneous cytoplasmic staining (Fig. 4). Similar changes were 
seen with G89S mutant GlialCAM, which was additionally detected in more 
intense labelling in neighbouring cells. A similar distribution was found with WT 
GlialCAM in Mlc1-/- mice. In Glialcam-/- and Glialcamdn/dn mice, MLC1 was 
diffusely distributed throughout the cytoplasm of adjacent astrocytes, but not in 
oligodendrocytic somata (Fig. 4). Since OLs lack MLC1, its effect on 
oligodendrocytic GlialCAM and ClC-2 cannot be cell-autonomous.  
Hence both GlialCAM and MLC1 were necessary for each other’s correct 
localization and for the correct targeting of ClC-2 in glial cells, whereas ClC-2 
disruption had no significant effect on GlialCAM (see also ref.12) and MLC1 
(Table 1). The changed localization of ClC-2 and MLC1 in the Glialcam mouse 
models is compatible with in vitro results7,12. However, the effect of MLC1 
deletion was unexpected because MLC1 is believed not to bind ClC-2 and to 
have no role in GlialCAM targeting7,12.  
 
GlialCAM trans interactions localize MLC1 and ClC-2 in vitro 
Our in vivo data agree with the effect of GlialCAM on ClC-2 and MLC1 
localization in transfected cells, but contrast with the missing impact of MLC1 on 
GlialCAM7,12. To systematically analyse the localization of all three proteins we 
separately transfected HeLa cells with different combinations of ClC-2, 
GlialCAM, and MLC1 and later combined these cells to form contacts upon 
further growth (Fig. 5). Immunofluorescent labelling revealed that GlialCAM 
expression in both cells was necessary and sufficient to direct ClC-2 or MLC1 to 
cell-cell contacts (Fig. 5a-c, filled arrows). This targeting did not require ClC-2 or 
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MLC1 to be present in both cells (Fig. 5a,b). Expression of ClC-2 or MLC1 
alone did not affect the localization of GlialCAM, MLC1 or ClC-2 in neighbouring 
cells even when they co-expressed two of these proteins (Fig. 5d-g). Hence 
homophilic interactions of GlialCAM in trans may suffice to anchor and 
concentrate GlialCAM at cell-cell contacts. Binding in cis of GlialCAM to ClC-2 
or MLC1 concentrates these latter proteins at the same site without requiring an 
interaction with ClC-2 or MLC1 on the adjacent cell.  
 
Modification of ClC-2 currents by GlialCAM and MLC1 in glia  
When overexpressed in Xenopus oocytes, HEK cells, or primary astrocytes, 
GlialCAM increases ClC-2 currents and almost abolishes its inward 
rectification12. To examine whether these changes occur in vivo we performed 
whole-cell patch-clamp experiments in brain slices (Figs. 6 and 7). Patch-pipette 
solutions contained CsCl to suppress K+-currents and the gap junction blocker 
carbenoxolone to electrically isolate the patched cell from the panglial 
network21. Control experiments with transfected HEK cells confirmed that 
carbenoxolone did not affect ClC-2 currents (Supplementary Fig. 3a-c). Na+-
currents were suppressed by replacing extracellular Na+ with N-methylD-
glucamine (NMDG+) (Supplementary Fig. 3f). We first measured BG (Fig. 6, 
Supplementary Fig. 3g-i) because they prominently express ClC-2, GlialCAM 
and MLC1 and display strongly changed ClC-2 localization upon disruption of 
GlialCAM or MLC1 (Fig. 2a). We initially identified BG by fluorescence in mice 
expressing enhanced green fluorescent protein (eGFP) under the control of the 
glial fibrillary acidic protein (GFAP) promoter22 and later by dye filling through 
the patch-pipette (Supplementary Fig. 3d,e). This labelling revealed no obvious 
differences in BG morphology among genotypes (Supplementary Fig. 3e). 
Surprisingly, BG Cl--currents did not display the linear current-voltage 
relationship expected from ClC-2/GlialCAM heteromers12 (Supplementary Fig. 
3a-c), but showed the slow activation by hyperpolarization (Fig. 6a) that is 
typical for ClC-2 (without GlialCAM)14.  Later an unusual apparent inactivation 
set in which became faster with hyperpolarization and appeared to reach 
completion after ~4 seconds  (Supplementary Fig. 3f). The absence of these 
currents from Clcn2-/- BG (Fig. 6c), however, identified them as ClC-2 currents. 
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 Whole-cell Cl--currents obtained from BG somata of Glialcam-/- or 
Glialcamdn/dn mice did not display the expected12 increased rectification, but 
lacked the apparent inactivation observed in WT glia (Fig. 6e,g,m, 
Supplementary Fig. 4a,c,d,f,h,i). Similar non-inactivating ClC-2 currents were 
observed with BG from Mlc1-/- mice (Fig. 6i,m, Supplementary Fig. 4e,j). 
Heterozygous Glialcam+/- BG showed currents similar to WT (Supplementary 
Figs. 4b,g,5d). These results might indicate that, rather than abolishing its 
rectification as in vitro12, in vivo GlialCAM causes ClC-2 to inactivate.  
However, the cell capacitance of Glialcam-/-, Glialcamdn/dn, Mlc1-/- and to 
a lesser extent of Clcn2-/- BG was increased and more variable compared to WT 
(Fig. 6k). The augmented capacitance suggested an increased cell volume 
which might change whole-cell currents by reducing the dissipation of Cl--
gradients and/or the electrical access to ion channels in distant processes. 
Indeed, when we superfused BG with hypotonic solution to induce cell swelling 
(which resulted in the expected increase in cell capacitance (Supplementary 
Fig. 5a)), the apparent inactivation of WT and Glialcam+/-  Cl--currents was 
attenuated or even abolished, whereas the non-inactivating currents of 
Glialcam-/- BG and background currents of Clcn2-/- BG were unchanged (Fig. 6 
b,d, Supplementary Fig. 5b-e). Conversely, exposure of Glialcam-/-, 
Glialcamdn/dn or Mlc1-/- BG to hypertonic solution partially reproduced the current 
‘inactivation’ observed in WT BG at isoosmolarity (Fig. 6f,h,j, Supplementary 
Fig. 5f-h). Hence, cell swelling likely contributes to the lack of apparent ClC-2 
inactivation in Glialcam-/- and Mlc1-/- mice. However, cell capacitance and the 
degree of ‘inactivation’ did not correlate across cells of different genotypes 
(Supplementary. Fig. 6). As WT and mutant BG cells rather segregated into two 
distinct groups, additional factors like the changed compartmentalization of ClC-
2 in mutant mice (Fig. 2a) or possibly loss of interaction with other proteins may 
play a role in suppressing the apparent ‘inactivation’ of ClC-2 currents. The 
decrease in current amplitudes upon hypertonic shrinkage (Fig. 6f,h,j) may be 
owed to reduced electrical accessibility of ClC-2 in cell processes or to the 
intrinsic osmosensitivity of ClC-213. 
 From our previous in vitro data12 we had expected a large decrease of 
ClC-2 current amplitudes with Glialcam ablation, but averaged current 
amplitudes of Glialcam-/- BG rather appeared larger than WT (Fig. 6a,e). When 
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normalized to cell capacitance, however, current amplitudes of Glialcam-/-, 
Glialcamdn/dn and Mlc1-/- BG were moderately smaller compared to WT when 
measured at early time points (Fig. 6l), and nearly unchanged at 1.5 seconds 
when WT currents were reduced by the apparent inactivation (Fig. 6m). The 
mild reduction in ClC-2 current density in Glialcam-/- and Mlc1-/- BG is consistent 
with the decreased ClC-2 expression in these cells (Fig. 2). 
 Whereas overall BG morphology appears normal in our mouse models, 
myelin vacuolization (shown below) pointed to pathological changes in OLs 
which were therefore included in our analysis (Fig. 7, Supplementary Fig. 3j-m). 
Their identity was confirmed by dye filling which did not reveal obvious 
morphological differences among the genotypes (Fig. 7l). Unlike BG, Cl--
currents of OLs lacked time-dependent activation by hyperpolarization (Fig. 7a). 
About 60% of these currents could be attributed to ClC-2 by comparison to 
Clcn2-/- OLs (Fig. 7a-c, Supplementary Fig. 7a). Consistent with effects of 
GlialCAM in heterologous expression12, Cl--currents of Glialcam-/- OLs were 
smaller and displayed the typical activation by hyperpolarization when corrected 
for background currents of Clcn2-/- mice (Fig. 7d,e). Although currents were 
small, Cl- currents of Mlc1-/- and Glialcam+/- OLs appeared similarly rectifying 
(Fig. 7f,g,j,k,n, Supplementary Fig. 7b,e). Currents from Glialcamdn/dn OLs, 
showed less voltage-dependent activation (Fig. 7h,i, Supplementary Fig. 7d), 
consistent with the observation that human mutations in GlialCAM Ig-domains 
interfere with its homophilic binding in trans, but not with its effect on ClC-2 
currents12. The membrane capacitance of Glialcam-/-, Glialcamdn/dn, Mlc1-/- and 
Clcn2-/- OLs was increased, although not quite to the same extent as in BG (Fig. 
7m, compare to Fig. 6k).  
Hence the effect of GlialCAM on ClC-2 currents known from 
heterologous expression12 (Supplementary Fig. 3a-c) can be observed in OLs, 
but not in BG (Table 1). Based on their increased capacitance, both types of 
glia appear to be swollen. 
 
Leukodystrophy in Glialcam Mlc1 and Clcn2 mouse models 
Brain sections from Glialcam-/-, Glialcamdn/dn and Mlc1-/- mice revealed myelin 
vacuolization that slowly progressed over several months (Fig. 8a). 
Vacuolization was most prominent in fibre tracts of the cerebellum, similar to 
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what was found in Clcn2-/- mice8. While the degree and time course of 
vacuolization was comparable across Glialcam-/-, Glialcamdn/dn and Mlc1-/- mice, 
they altogether developed vacuolization more slowly and less severely than 
Clcn2-/- mice. Not until around one year of age was discrete vacuolization 
apparent in cerebellar fibre tracts of Glialcamdn/+ mice. 
After appearing in the cerebellum, vacuolization extends to several brain 
regions in Clcn2-/- mice8. By contrast, myelin vacuolization was largely restricted 
to the cerebellum of Glialcam-/-, Glialcamdn/dn and Mlc1-/- mice even after one 
year (Supplementary Fig. 8a). In contrast to early retinal degeneration of Clcn2-/- 
mice9, the retinae of Mlc1 and Glialcam mouse models were unaffected up to 
one year of age (Supplementary Fig. 8b). Electron microscopy revealed 
vacuoles in myelin sheaths of cerebellar axons from Glialcam-/-, Glialcamdn/dn 
and Mlc1-/- mice (Fig. 8b). Modest pathological changes were also seen in 
somata of astrocytes and OLs. Their cytoplasm appeared less electron dense 
and occasional vacuoles could be observed in astrocytes (Supplementary Fig. 
9). 
 One may hypothesize that the leukodystrophy observed in Glialcam-/- and 
Mlc1-/- mice might be entirely due to the associated changes in ClC-2 and the 
resulting consequences for ion homeostasis8. In this case, the additional loss of 
GlialCAM in Clcn2-/-/Glialcam-/- mice should not increase the severity of 
leukodystrophy over that of Clcn2-/- mice. However, in mice lacking both 
proteins vacuolization appeared earlier and was more severe (Fig. 8c). We also 
crossed Glialcam-/- with Clcn2hyp/hyp mice that express ClC-2 at <10% of WT 
levels (Supplementary Fig. 1f-i). Clcn2hyp/hyp mice lacked white matter 
vacuolization at 17 weeks of age (Fig.8d), demonstrating that a small amount of 
ClC-2 suffices to maintain myelin integrity as long as ClC-2 is correctly targeted 
and regulated by GlialCAM. Furthermore, the reduction in ClC-2 protein levels 
in Glialcam and Mlc1 mouse models is per se not responsible for myelin 
vacuolization, as their ClC-2 levels are considerably higher than in the 
hypomorphic mouse. Crossing Clcn2hyp/hyp with Glialcam-/- mice, however, 
strongly increased their myelin vacuolization (Fig. 8d), suggesting that ClC-2 
and GlialCAM operate in the same pathogenic pathway. 
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Discussion 
 
We have analysed several genetic mouse models for human leukodystrophy to 
dissect the pathogenic roles of the multipass membrane protein MLC1, the cell 
adhesion molecule GlialCAM and the Cl--channel ClC-2. The clustering of these 
proteins at glial plasma membrane domains depended on the presence of both 
MLC1 and GlialCAM, but not on ClC-2. The reduction in oligodendrocytic Cl--
currents in Glialcam and Mlc1 mouse models indicated that impaired glial ion 
homeostasis contributes to MLC disease. Mice lacking both ClC-2 and 
GlialCAM, however, showed that MLC leukodystrophy cannot be attributed 
solely to a loss of ClC-2. 
 GlialCAM can bind MLC12 and ClC-212 within the same cell and this 
binding might be mutually exclusive12. GlialCAM also forms cis-homooligomers 
within the membrane4,7. Homooligomer formation does not require the 
cytoplasmic carboxy-terminus4, but the relevant binding sites are not yet known. 
GlialCAM also interacts with itself in trans through its extracellular Ig domains. 
These domains might interact also with other proteins. Indeed, GlialCAM 
overexpression increases adhesion to the extracellular matrix and modulates 
cell migration, and GlialCAM localizes to cell protrusions in spread cells4,23,24. 
By accumulating at cell-cell contacts through homophilic interactions in 
trans, GlialCAM targets ClC-2 and MLC1 to these sites in cultured cells2,12,25 
and stabilizes MLC125. By contrast, ClC-2 levels do not increase with GlialCAM 
co-transfection12, and MLC1 expression lacks discernible effects on either 
GlialCAM7 or ClC-212,16. The present systematic analysis of cell pairs revealed 
that accumulation of ClC-2 or MLC1 at cell-cell junctions only required 
GlialCAM, but neither ClC-2 nor MLC1, to be present in both cells. 
 Our work demonstrates that GlialCAM localizes ClC-2 and MLC1 to 
distinct sites also in vivo. Without GlialCAM, MLC1 and ClC-2 accumulated in 
BG somata. We were surprised that disruption of MLC1 also mislocalized 
GlialCAM and ClC-2. Because MLC1 may not bind ClC-212,16, its effect on ClC-2 
might be mediated by the mislocalization of GlialCAM. However, the effect of 
MLC1 on GlialCAM is equally unexpected since knock-down of MLC1 in 
astrocytes changed neither the expression nor the localization of GlialCAM7. 
Does MLC1 stabilize the GialCAM-GlialCAM interaction in vivo, an effect easily 
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overlooked in vitro because of overexpression? Or does MLC1 serve as co-
receptor for GlialCAM, with GlialCAM/MLC1 binding in trans not only to 
GlialCAM, but also to other proteins present in brain but absent in cell culture? 
 Surprisingly, Mlc1 disruption also destabilized GlialCAM and ClC-2 in 
OLs although they apparently lack MLC12,19,20. MLC1 expression appears to be 
restricted to astrocytes since Mlc1-/- mice now revealed that previously reported 
axonal labelling for MLC120,26 was unspecific. ClC-2, GlialCAM and MLC1 
cluster at oligodendrocytic somata close to Cx478,12 which forms gap junctions 
with astrocytes27.  We speculate that astrocytic GlialCAM might be unstable 
without astrocytic MLC1, which in turn may destabilize the ClC-2/GlialCAM 
complexes on OLs because they now lack their cognate interaction partner. 
 The G89S mutation introduced into Glialcamdn mice is found in patients 
with dominantly inherited MLC2B disease2. It changes a residue in the 
extracellular Ig-like domain and likely interferes with binding to ligands. Indeed, 
when GlialCAM carries disease-causing mutations in Ig domains (e.g. G89D 
that affects the same residue as G89S), neither GlialCAM nor MLC1 or ClC-2 
accumulate at cell-cell junctions2,12. However, mutants like G89D can still bind 
MLC17 or ClC-2 and can modify its Cl--currents12. Likewise, the GlialCAM G89S 
mutant was mislocalized in Glialcamdn/dn mice in vivo and consequently failed to 
correctly localize ClC-2 and MLC1. MLC1 abundance was robustly decreased in 
Glialcam-/- mice, suggesting an increased stability of GlialCAM/MLC1 
complexes. The GlialCAM mutant, even though mislocalized, partially retained 
its stabilizing effect on MLC1, in particular outside the cerebellum (Fig. 1c,d). No 
such stabilization was observed for ClC-2, possibly indicating that mutant 
GlialCAM binds ClC-2 less strongly than MLC1. Western blots suggested that 
ClC-2 is more efficiently stabilized by GlialCAM in cerebellum than in the rest of 
the brain. However, ClC-2 is also expressed in neurons, where its expression 
should not depend on GlialCAM. Hence this result may be owed to a higher glial 
versus neuronal ClC-2 expression in the cerebellum. 
 ClC-2 is a widely expressed plasma membrane Cl--channel that slowly 
activates upon hyperpolarization, cell swelling, and moderately acidic 
extracellular pH13,15. These characteristics were observed in heterologous 
overexpression and in native cells9,28 including neurons29,30 and astrocytes31-33. 
Upon heterologous co-expression, GlialCAM increases ClC-2 currents and 
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drastically changes their properties from inwardly rectifying to a nearly ohmic 
current-voltage relationship, an effect that does not require GlialCAM-GlialCAM 
trans interactions12. It has remained unclear whether the linearization of ClC-2 
currents also occurs in vivo or results from non-physiological overexpression. 
Indeed, other groups have shown that native astrocytes display typical 
hyperpolarization-activated ClC-2 currents31-34. Strikingly, we observed the 
expected effect of GlialCAM on Cl--currents only in OLs, although BG also co-
express ClC-2 and GlialCAM. Glialcam-/- OLs displayed typical inwardly 
rectifying ClC-2 currents, whereas similarly background corrected currents from 
WT cells were larger and neither showed time-dependence nor inward 
rectification.  
In contrast to OLs, BG showed hyperpolarization-activated Cl--currents 
with or without GlialCAM. Current amplitudes at Glialcam-/- or Mlc1-/- BG somata 
were moderately increased, but when normalized to membrane capacitance 
they were rather decreased. Cell swelling, as indicated by increased membrane 
capacitance of Glialcam-/- or Mlc1-/- BG, may have improved the electrical 
accessibility of BG processes that retain some ClC-2. Indeed, current 
amplitudes were reduced when Glialcam-/-, Glialcamdn/dn and Mlc1-/- BG were 
shrunk by exposure to hypertonicity. 
 Why did GlialCAM change the rectification of ClC-2 in OLs, but neither at 
BG somata nor in astrocytes31-34 if all three cell types co-express these two 
proteins? One may hypothesize that MLC1, which is expressed in BG but not in 
oligodendroyctes, may interfere with the biophysical effect of GlialCAM on ClC-
2 currents. However, the additional expression of MLC1 did not change the 
effect of GlialCAM on ClC-2 currents in Xenopus oocytes12. An easy 
explanation would be a higher GlialCAM/ClC-2 ratio in OLs, an assumption 
difficult to verify by immunohistochemistry. Bolstering this notion, 
overexpression of GlialCAM in native astrocytes increased Cl--currents and 
reduced their rectification12. However, the strong effect of GlialCAM on ClC-2 
localization and abundance in BG suggests that the majority of ClC-2 is 
normally anchored and stabilized by GlialCAM. This anchoring might require 
less GlialCAM per ClC-2 than the change in channel rectification. The 
stoichiometry of ClC-2/GlialCAM binding is currently unknown. One could 
speculate that binding of one GlialCAM molecule to a homodimeric ClC-2 
15 
 
channel suffices for anchoring, but that two (or more) GlialCAM β-subunits are 
required to change the gating of the two ClC-2 pores35.  
 An increase of up to two-fold in membrane capacitance of BG and OLs 
suggested that their volume was increased when either MLC1, GlialCAM, or 
ClC-2 was lacking. Independent evidence for cell swelling was obtained from 
the apparent inactivation of ClC-2 currents in WT BG that could be reversed by 
hypoosmotic swelling and was abolished in Glialcam-/- cells.  
A common denominator for the increase in glial cell volume may be a 
reduction of ClC-2 currents. Loss of ClC-2, which is swelling-activated13,15 and 
constitutively open when modified by GlialCAM12, may cause cell swelling 
because the Cl- equilibrium potential of glia36-38 predicts an outward direction of 
Cl--flux and associated water transport. Even though ClC-2 currents at BG 
somata were not reduced in Glialcam or Mlc1 mouse models, ClC-2 was 
strongly decreased along BG processes. At these sites, which escape our 
patch-clamp analysis, ClC-2 currents might be linearized and enhanced by 
GlialCAM and might influence cell volume. MLC1 was reported39 to stimulate 
the ubiquitous volume-regulated anion channel (VRAC) that is distinct from 
ClC-213 and is not known at the molecular level40. siRNA-mediated knock-down 
of GlialCAM or MLC1 reduced VRAC currents25. This effect is probably indirect 
as AQP4 knock-down also reduced astrocytic VRAC currents41. Since both 
ClC-2 and VRAC mediate Cl--currents, and because membrane capacitance 
was also increased in Clcn2-/- mice, the simplest explanation for glial swelling 
remains a lack of ClC-2. Another factor may be the lack or downregulation of 
GlialCAM-mediated adhesion in Glialcam and Mlc1 mouse models, 
respectively. The somewhat larger increase in cell capacitance of BG from 
Glialcam-/- and Mlc1-/- mice compared to Clcn2-/- mice is compatible with this 
notion.  
 Disruption of all three genes, i.e. Clcn2, Glialcam, and Mlc1, entails 
leukodystrophy in mice and humans. Since GlialCAM binds to both ClC-2 and 
MLC1 and disruption of either Glialcam or Mlc1 affects the localization and 
abundance of the two other proteins, this raises the question whether loss-of-
function mutations in those genes cause leukodystrophy through a common 
pathway.  
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Four observations suggest loss of ClC-2 function as the prime suspect 
for such a pathway: First, ClC-2 localization was changed upon Glialcam or 
Mlc1 disruption, whereas lack of ClC-2 had no detectable effect on either 
GlialCAM or MLC1. Second, OLs, the cells mainly affected by vacuolization, 
showed decreased ClC-2 Cl--currents in both Glialcam-/- and Mlc1-/- mice. As 
OLs lack MLC12,19,20, the myelin vacuolization in Mlc1-/- mice may result from 
the secondary loss of ClC-2 and/or GlialCAM. Third, leukoencephalopathy was 
more severe in Clcn2-/- mice than in Glialcam-/- or Mlc1-/- mice which retain 
reduced ClC-2 levels in glia. The fact that disruption of Clcn2, but not of 
Glialcam or Mlc1, additionally causes testicular and retinal degeneration9 is 
owed to the wider expression pattern of ClC-214. Fourth, when Glialcam-/- mice 
were crossed with Clcn2hyp/hyp mice that express <10% of WT ClC-2 levels but 
lack leukodystrophy, myelin vacuolization of resulting Glialcam-/-/Clcn2hyp/hyp 
mice was more severe than in Glialcam-/- mice, suggesting a common 
pathogenic pathway. 
We have previously hypothesized8 that ClC-2 disruption causes 
leukodystrophy by disturbing the buffering of extracellular ions analogous to the 
postulated role of ClC-2 in regulating the milieu extérieur of Sertoli cells and 
photoreceptors9. Indirect support for this model came from the co-localization at 
astrocytic endfeet of ClC-2 with the K+-channel Kir4.142,43, whose inactivation 
also entails leukodystrophy42,44 as does ablation of glial connexins 32 and 4745-
47. These proteins are thought to co-operate in ‘K+ siphoning’48. This model 
states that K+ released from neurons during action potential repolarization is 
taken up by Kir4.1 into the connexin-linked astroglial network and is then 
equilibrated with serum through astrocytic endfeet at blood vessels. Cl--fluxes 
through ClC-2 may be needed for an overall electroneutral transport across glial 
plasma membranes during K+ siphoning. The linearization of ClC-2 currents by 
GlialCAM may be important for K+ siphoning as a rise of extracellular K+ upon 
neuronal activity is expected to depolarize the glial membrane and shut down 
ClC-2. Dysregulation of Cl--concentrations in the small extracellular clefts might 
also change extracellular pH through Cl-/HCO3- exchangers9. Cell-type specific 
disruption of ClC-2 will be needed to clarify whether leukodystrophy results from 
a loss of ClC-2 currents in OLs, astrocytes, or both. 
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Genetic evidence, however, showed that GlialCAM loss elicits 
leukodystrophy only in part through ClC-2. Since pathology was more severe in 
Clcn2-/-/Glialcam-/- than in Clcn2-/- mice, GlialCAM ablation has additional, 
ClC-2-independent pathogenic effects. The lack GlialCAM-mediated cell 
adhesion may also come into play, but the low abundance of GlialCAM in 
myelin sheaths and the prominence of other adhesion molecules49 makes a 
direct role in myelin vacuolization unlikely. Moreover, vacuolization developed 
after apparently normal brain and myelin development, an observation that is 
important in view of the report24 that overexpression of GlialCAM in U373-MG 
glioblastoma cells induces glial differentiation. It seems more likely that the 
downregulation or mislocalization of other proteins like MLC1 may contribute, 
together with changes in ClC-2, to MLC pathology. Unfortunately, except for its 
role in leukodystrophy and its protein interaction partners, not much is known 
about the function of MLC1. 
 This work has revealed important functional interactions in vivo of ClC-2, 
GlialCAM and MLC1 (Table 1), three proteins underlying human 
leukodystrophies. In vitro studies had shown that the adhesion molecule 
GlialCAM directly interacted with either MLC1 or ClC-2, changing their 
subcellular localization and profoundly altering ClC-2 currents12. However, no 
effect of MLC1 on GlialCAM or ClC-2 had been described. Here we showed that 
in addition to GlialCAM also MLC1, but not ClC-2, is important for tethering the 
protein complex to specific plasma membrane domains of both astrocytes and 
OLs in vivo. Although GlialCAM, together with MLC1, anchors ClC-2 in both 
types of glia, the rectification of ClC-2 Cl--currents was only abolished in OLs. 
Hence the localizing effect of GlialCAM can be dissociated from its impact on 
ClC-2 channel function. Reduction or change in ClC-2 currents is common to all 
forms of leukodystrophy studied here. Hence mutations in both GLIALCAM and 
MLC1 may cause leukencephalopathy in part through impaired brain ion 
homeostasis. Crosses between Clcn2-/- and Glialcam-/- mice, however, show 
that loss of GlialCAM or MLC1 has additional pathogenic effects unrelated to 
ClC-2. The unexpected similar effects of Mlc1 and Glialcam ablation on their 
protein partners rationalize the undistinguishable symptomatology of the MLC1 
and MLC2A forms of human leukodystrophy. 
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Methods 
 
Mice 
All animal experiments were approved and in compliance with LaGeSo, Berlin, 
Germany, and the Animal Care and Ethics Committee of the IDIBELL and the 
rules set by the Government of Cataluña, Spain.  Mlc1-/- mice were generated 
by iCS (Institut Clinique de la Souris, Strasbourg, France). The targeting vector 
was obtained from amplification of BAC RP 24-467H19 (5’ arm) and from 
amplification of 129S2/SvPas genomic DNA (3’ arm).  Exons 2 and 3 were 
flanked by loxP sites. Exon 3 contained additionally a neomycin cassette 
flanked by FRT sites. The targeting vector was introduced into the H129 ES cell 
strain by electroporation and positive clones were selected by PCR. 
Homologous recombination was confirmed by Southern blotting and 
chromosomal integrity was checked by karyotyping. Correctly targeted ES cell 
clones were injected into C57BL/6 blastocysts and chimeric animals were 
crossed to FLPrecombinase expressing ‘deleter’ mice (in C57BL/6 background) 
to remove the neomycin resistance cassette. To generate Mlc1-/- mice, Mlc1lox/lox 
mice were crossed to Cre-deleter mice to remove the floxed exons 2 and 3. 
PCR genotyping was performed using primer sequences 
ctgaatctagatgagtttgggtggc (P1), gaaaccctctaattgtagtaagtg 
gaaaaccctctaattgtagtaagtg (P2) and gcaccacagcaccacaacatgc (P3). 
Mice carrying the dominant negative mutation G89S in exon 2 of the 
Gliacam (Hepacam) gene (Glialcamdn/dn) and additionally having exons 2-4 
flanked by loxP sites were generated by TaconicArtemis (Cologne, Germany) 
and were kept in a C57Bl/6 genetic background. The targeting vector was 
generated from BAC clones of the C57BL/6J RPCIB-731 library. Two positive 
selection markers, a neomycin resistance cassette flanked by FRT sites and a 
puromycin resistance cassette flanked by F3 sites, were inserted into intron 1 
and 4 respectively. The targeting vector was introduced into the C57BL/6 NTac 
ES cell line by electroporation and positive clones were selected by PCR and 
homologous recombination was confirmed by Southern blotting.  Correctly 
targeted ES cell clones were injected into C57BL/6 blastocysts and chimeric 
animals were crossed to FLPe recombinase expressing ‘deleter’ mice (in 
C57BL/6 background) to remove neomycin and puromycin resistance 
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cassettes. To generate Glialcam-/- mice,  Glialcamdn/dn mice were crossed to 
Cre-deleter mice (in C57BL/6 background) to remove the ‘floxed’ exons 2-4. 
PCR genotyping was performed using primer sequences ctatttcctgccatactacctcc 
(P1), tgcctttgctttctcagtcc (P2) and tgagcacagacgcaactcc (P3). 
Generation of Clcn2-/- mice has been described previously9. Mice 
expressing low levels of ClC-2 (hypomorph Clcn2, Clcn2hyp/hyp) were generated 
unintentionally by insertion of loxP sites flanking exons 2 and 3 of Clcn2. A 10.6 
kb fragment of R1 ES cell genomic DNA containing exons 1 to 21 of Clcn2 were 
cloned into pKO Scrambler Plasmid 901 (Lexicon Genetics Inc.). A neomycin 
resistance cassette flanked by loxP sites and AscI sites at both ends was 
inserted into the ClaI site between exon 1 and 2 in a double-blunt manner. A 
third loxP site and an additional EcoRV site to aid Southern blot analyses were 
inserted between exons 3 and 4. The targeting construct was introduced into R1 
ES cells by electroporation and positive clones were selected by Southern blot 
analyses. Selected positive clones were then electroporated with a Cre 
recombinase expression construct for removal of the neomycin resistance 
cassette. Clones that had the neomycin resistance cassette removed were 
chosen for injection into C57BL/6 blastocysts. PCR genotyping was performed 
using primers ttaggctggaatttgcccgagagg(P1), gaggaggtgagcaagacaaaaggg (P2) 
ggcaaaggctggcgaggtaacttc (P3) and agggaaggcaaggctagagaaggc  (P4). 
Clcn2-/-, Mlc1-/- and Clcn2hyp/hyp mice were in a C57BL/6-129/Svj mixed genetic 
background, while Glialcam-/- and Glialcamdn/dn were in a C57BL/6 background. 
For some electrophysiological measurements mice were crossed to a 
transgenic line expressing eGFP under the control of the human GFAP 
promotor22 (FVB/N background), resulting in eGFP expression in astrocytes.  
Experiments were performed at different ages (indicated in figure legends) and 
both sexes were used interchangeably. 
 
Generation of antibodies 
Antibodies against mouse ClC-2 were raised in rabbits against two peptide 
sequences of different length corresponding to the extreme C-terminus: 
(C)WGPRSRHGLPREGTPSDSDDKSQ  (used for Western blotting) and 
(C)HGLPREGTPSDSDDKSQ (by Biogenes, Berlin, Germany; used for 
immunofluorescence staining). A cysteine in the native protein sequence was 
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replaced by the highlighted serine to prevent coupling of this residue to the 
carrier protein. 
GlialCAM-specific antibodies used for Western blots were raised in 
rabbits to peptide (C)LKDKDSSEPDENPATEPR, those used for 
immunostainings were raised in guinea pigs to peptide 
(C)AGVQRIREQDESGQVEISA. Both peptide sequences correspond to non-
overlapping parts of the intracellular C-terminal region of mouse GlialCAM. 
Antibodies recognizing the N-terminus of mouse MLC1 (used for 
immunostaining) were raised in rabbits and guinea pigs against peptide 
TREGQFREELGYDRM(C)20. Antibodies to the MLC1 C-terminus (used for 
Western blotting) were raised in rabbits against peptide 
CPQERPAGEVVRGPLKEFDK. 
Generation of antibodies was performed by Pineda Antibody Services 
(Berlin, Germany), unless indicated otherwise. “(C)” indicates cysteines not 
included in native protein sequence that were added to facilitate coupling to 
carrier protein. Antibodies were affinity purified from serum using the 
immunizing peptide. 
 
Western blot analyses 
For Western blot analyses membrane fractions were isolated from mouse 
tissue. To this end tissue homogenate was prepared  in 20 mM Tris-HCl pH 7.4, 
140 mM NaCl, 2 mm EDTA with protease inhibitors (4 mM Pefabloc and 
Complete EDTA-free protease inhibitor cocktail, Roche) using a glass Dounce 
homogenizer and cleared by centrifugation for 10 mins at 1000 x g. Membrane 
fractions were pelleted from the cleared homogenate by ultracentrifugation for 
30 mins at 270,000 x g, and the pellet was resuspend by sonification in 50 mM 
Tris pH 6.8,  140 mM NaCl, 2 mM EDTA with protease inhibitors. Equal 
amounts of protein were separated by SDS page and blotted onto 
nitrocellulose. Blots were reprobed with mouse anti-ß-actin (Clone AC-74, 
Sigma A2228, 1:5000) as loading control. 
 
Immunohistochemistry 
Deeply anaesthetized mice were perfused with 1% paraformaldehyde (PFA) in 
PBS and 6 µm sagittal cryosections were prepared from brains. Sections were 
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postfixed with 1% PFA/PBS for 10 mins, permeabilized with 0.2% Triton-X100 
in PBS and blocked with 3% bovine serum albumin (BSA) in PBS. Antibodies 
were diluted in blocking buffer. Incubation with primary antibody (see below for 
dilution) was performed at 4 °C overnight, incubation with secondary antibodies 
(1:1000) coupled to Alexa fluorophores (Molecular Probes) was carried out for 1 
hr at RT. Nuclei were stained with DAPI (Sigma). In addition to the self-
generated primary antibodies described above the following commercial 
antibodies were used: mouse anti-GFAP (clone G-A-5, Sigma G3893, 1:1000), 
mouse anti-S100ß (clone SH-B1, Sigma S2532, 1:1000), mouse anti-APC 
(clone CC1, Merck Millipore OP80, 1:200) and rat anti-heparan sulfate 
proteoglycan (perlecan, clone A7L6, Merck Millipore MAB1948P, 1:2000) and 
goat anti-aquaporin-4 (Santa Cruz sc-9888, 1:50). The rabbit anti-Kir4.1 was 
kindly provided by S.Takeuchi50. Images were acquired using an LSM510 
confocal microscope and ZEN software (Zeiss). 
 
Histology 
For histological analyses of brains and eyes, mice were perfused with 4% 
PFA/PBS and organs were postfixed overnight. Hematoxylin-eosin staining was 
performed on 6 µm paraffin sections of brains and eyes. 
 
Electron microscopy 
For ultrastructural studies, deeply anaesthetized mice were transcardially 
perfused with 4% paraformaldeyhde (PFA) and 2.5 % glutaraldeyhyde (GA) in 
0.1 M phosphate buffer (PB) (pH 7.4). The brains were removed and cut 
vertically into two halves. The brain samples were postfixed in the same fixative 
overnight at 4°C. Brains were cut into 150 µm sagittal sections of the 
cerebellum with a Leica vibratome. Cerebellum sections were cut into 1 mm3 
fragments. They were rinsed with 0.1 M phosphate buffer (PB) (pH 7.4) and 
postfixed with 2% aqueous osmium tetroxide (OSO4) and 1.5 % potassium 
hexacyanoferrate (K3[Fe(CN)6]) for 30 minutes. After rinsing with 50% ethanol 
sections were stained en bloc with 1% uranylacetate (UA) for 1 h in 70% 
ethanol. Fragments were dehydrated in graded ethanol, followed by infiltration 
of propylene oxide and embedding in Epon (Electron Microscopic Sciences, 
Hatfield, PA, USA). Ultrathin sections (60 nm) were prepared with a Reichert 
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Ultracut S, stained in 5% uranylacetate (UA) and 0.4% lead citrate 
((C6H5O7)2Pb3). Stained ultrathin sections were examined with a Zeiss 902 at 
80 kV and a Fei Tecnai G F20 at 200 kV. Photographs were taken with a 
Megaview 3 Camera and a Gatan Ultrascan 1000 Camera. Two mice per 
genotype were examined, with more than 10 ultrathin sections each and which 
displayed consistent results. 
 
Molecular biology 
For quantitative real time PCR (qRT-PCR) total RNA was isolated from 
cerebellum of 11 to 18 week old mice using the RNeasy lipid tissue mini kit with 
on-column DNase digestion (Qiagen). cDNA was synthesized from 1 µg of RNA 
using Superscript II reverse transcriptase (Invitrogen). PCR reactions were 
prepared using Power Sybr Green PCR Master Mix (Applied Biosciences) and 
ran in triplicates in a StepOnePlus Real-Time PCR System with StepOne 
Software (Applied Biosystems) to monitor amplification and melting curves. 
Relative expression of mutant mice compared to wild type siblings was 
calculated using the ∆∆CT method and ß-actin as internal control. The following 
primers were used: gaccgcctaaaatcagaagca andtggctctgtagcagggtttt for 
Glialcam; tcagtgcgattcccaactttca and ggaccgggccgaaatgat for Mlc1. Primer 
sequences for Clcn2: cagtgactgcaaaatcgaccc and  cataagcatggtccactccca and 
for ß-actin: tgtgatggtgggaatgggtcagaa and tgtggtgccagatcttctccatgt as described 
previously8,51. Missplicing in Clcn2hyp/hyp was detected by semiquantitative 
reverse transcription PCR. Total RNA was isolated from brain using Trizol 
reagent (Invitrogen) and cDNA synthesis was performed as described above. 
Subsequently PCR was performed using the following primer sequences: 
atggcggctgcaacggctg and aggttagcccaatgaccttagc.  Expression constructs for 
mouse Glialcam and Mlc1 were generated by PCR using full-length cDNA 
clones (SourceBioScience) as templates. Where applicable C-terminal 
haemagglutinin (HA)-tags were added by PCR and constructs were cloned into 
the pcDNA3.1mammalian expression vector (Invitrogen). The cDNAs for rat 
Clcn2 and human Glialcam were cloned in the pFROG vector for expression 
with the mammalian CMV promoter. 
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Cell culture/transfection 
HeLa cells (DSMZ, Germany, ACC 57, lot 17) were transfected with Clcn2, 
Glialcam or Mlc1 expression constructs using polyethylenimine (PEI). One day 
post transfection, cell were split and seeded onto coverslips. Three days after 
transfection cells were fixed with 4% PFA/PBS, permeabilized with 0.2% Triton-
X100/PBS and subjected to antibody staining as described for 
immunohistochemistry on tissue sections. 
 
Electrophysiological analysis of glial cells in brain slices 
Unless specified, concentrations are in mM and all solutions for incubating 
slices were constantly oxygenated with carbogen (5% CO2 in O2).  Mice (3-4 
weeks old of both gender) were deeply anesthetized and either 200µm sagittal 
sections for Bergmann glia (Bg) or 150µm coronal sections for corpus callosum 
OLs were prepared using a vibrating microtome (Leica VT1200S, Germany) in 
“low Ca2+“ aCSF containing: 134 NaCl, 2.5 KCl, 10 glucose, 26 NaHCO3, 1.25 
K2HPO4, 1.3 MgCl2, and 0.2 CaCl2 and adjusted to pH 7.4 with NaOH and to 
325±5 mOsm/kg.  Sagittal slices were allowed to recover in standard aCSF (2 
CaCl2) for at least 45 minutes at room temperature. Coronal slices, following 
sectioning, were first heated at 37°C for 30 minutes in standard aCSF before 
transferring to room temperature.  Measurements were performed at room 
temperature. Slices were adhered to poly-L-lysine coated cover slips and 
transferred to a recording chamber (Luigs & Neumann, Germany) with constant 
perfusion of aCSF (1-2mL/minute) and mounted to an upright microscope 
equipped with a 60x water immersion objective and both differential interference 
contrast and fluorescence optics (Olympus BX51WI).  Patch pipettes were 
fabricated from glass capillaries (World Precision Instruments PG52151-4, 
USA) (DMZ Universal Puller, Germany) and filled with an intracellular solution 
containing: 140 CsCl, 1 MgCl2, 10 Hepes, 5 EGTA, 0.2 disodium carbenoxolone 
(Sigma-Aldrich) and adjusted to pH 7.3 with CsOH and to 290 mOsm/kg.  Either 
0.5 mg/mL Alexa Fluor 488 (Life Technologies A10436) or 2mg/mL biocytin 
(Sigma B4261) was added to the patch pipette to confirm cell identity during the 
recording or following slice fixation for post-hoc analysis, respectively.  Ag-AgCl 
wires were used for recording and reference electrodes.  Using a computer 
controlled microelectrode amplifier (Multiclamp 700B) and acquisition software 
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(Clampex 10.3, Molecular Devices, USA), patch pipettes typically registered 
resistances of 5-7MΩ with a small voltage pulse.  For patch clamping of Bg and 
OLs in the tight seal configuration (>1 GΩ), small somata adjacent to the larger 
Purkinje cells were selected, and small somata typically grouped in a row 
parallel to fibres in white matter tracts were selected, respectively.  On 
acquisition of the conventional whole cell configuration, large voltage-
independent currents were seen in both Bg and OLs on short voltage pulses 
from +40mV to -100mV from a holding potential of -10mV.  Morphologically, Bg 
typically had two or three thin processes radiating across the molecular layer 
and terminating in the pia.  OLs typically had processes that were sparsely 
branched and were orientated in parallel with myelinated fibres.  To isolate ClC-
2 currents, slices were perfused with a Na+ and K+-free extracellular solution   
containing: 117 NMDG-Cl, 23 NMDG-HCO3, 5 CsCl, 1.3 MgCl2, 9 glucose, 2 
CaCl2, 0.2 Na2-carbenoxolone and adjusted to pH 7.3 with CsOH and 295±5 
mOsm/kg.  Typically at least 10-15 minutes were needed before the membrane 
conductance stabilized upon perfusion with the NMDG-Cl bath solution. To elicit 
ClC-2 currents, voltage steps from +40mV to up to -120mV from a holding 
potential of -10mV were used.  A final 1s voltage step at +40mV was applied 
before returning to the holding potential.  Signals were digitized at 10 KHz, 
filtered at 2 kHz, and stored for off-line analysis.  Using the standard membrane 
test function in Clampex software, membrane capacitance and resistances were 
obtained on-line at the end of the experiment using a small 5mV pulse from a 
holding potential of -10mV.  In some experiments, slices were perfused with 
either a hypotonic diluted NMDG-Cl solution (80%) to 235±5mOsm/kg, or a 
hypertonic NMDG-Cl with sucrose added to 325±5 mOsm/kg. Averaging, 
normalizing and subtracting trace profiles were done off-line using ClampFit 
10.3 (Molecular Devices). Current profiles were acquired using the same 
voltage pulse protocol (1.5s steps from +40mV to -120mV including a 1s tail 
current at +40mV before returning back to the holding potential of -10mV).  
Currents from each cell were averaged by genotype to obtain an average 
current (I) profile.  In other analyses, the average current (I) profile from each 
genotype was divided (‘Arithmetic tool’) by its average capacitance (C) to obtain 
the average current density (I/C) profile.  For trace subtraction, either I or I/C 
trace profiles from Clcn2-/- mice were subtracted (‘Arithmetic tool’) from the 
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respective I or I/C trace profiles from WT, Glialcam-/-, Mlc1-/-, Glialcamdn/dn, or 
Glialcam+/- animals to examine the ClC-2 specific I or I/C trace profiles in the 
different mouse models. 
 
Processing of biocytin-filled cells in brain slices 
 Following patch clamp experiments, slices were fixed in 4% PFA (in 1x PBS) 
overnight at 4°C.  Slices were washed in Wash buffer containing 0.1M 
phosphate buffer pH7.4 and 0.25% Triton-X100.  Slices were blocked in Wash 
buffer containing 5% normal goat serum for 2 hours at room temperature.  For 
secondary detection, Alexa Fluor 555 Streptavidin (Life Technologies) was 
added to the slices at a 1:500 dilution for overnight incubation at 4°C.  Slices 
were washed and mounted on gelatinized slides with Fluoromount G 
(SouthernBiotech).  Images were acquired with a confocal microscope (Zeiss 
LSM 510).  
 
Patch clamp measurements in HEK cells 
 HEK293 cells were transfected in 12 well plates at approximately 50% 
confluency with either 0.5μg of plasmid encoding rat ClC-2 or 0.25μg of plasmid 
encoding rat ClC-2 and 0.25μg of plasmid encoding human Glialcam.  All cells 
were co-transfected with a reporter plasmid expressing GFP. Using a 
microelectrode amplifier (Multiclamp 700B) with acquisition software (Clampex 
10.3, Molecular Devices, USA), whole cell currents were measured by patch 
clamp analysis two days after transfection.  When filled with an intracellular 
solution containing (in mM):  140 CsCl, 1 MgCl2, 10 Hepes, and 5 EGTA 
adjusted to pH 7.3 and to 290 ± mOsm/kg, patch pipettes registered resistances 
of 4-5 MΩ.  The bath solution was composed of (in mM): 140 NaCl, 2 MgSO4, 
2CaCl2, 10 Hepes, 22 sucrose and adjusted to pH7.4 with NaOH and to 325 ± 
5mOsm/kg with sucrose.  ClC-2 currents were elicited with 1s voltage pulses 
from +40mV to -120mV and a final voltage pulse at +40mV before returning 
back to the holding potential of -10mV.  Individual cells were first measured in 
normal bath solution and again following superfusion of bath solution containing 
200μM disodium carbenoxolone.  Signals were digitized at 10 KHz, filtered at 2 
kHz, and stored for off-line analysis using ClampFit software. 
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Statistics.  Statistical significance was assessed between two groups using the 
nonparametric Mann-Whitney test (Prism, GraphPad software, USA).   
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Figure legends 
 
Figure 1 | Expression of ClC-2 GlialCAM and MLC1 in Glialcam and Mlc1 
mouse models. (a) Western blots for ClC-2 (top), GlialCAM (middle) and MLC1 
(bottom) of membrane fractions isolated from organs of WT, and  Clcn2-/-, 
Glialcam-/- or Mlc1-/- mice, respectively (age: 10-12 weeks). For ClC-2 equal 
amounts of protein per organ were loaded, whereas for GlialCAM and MLC1 
blots, ten times more protein was loaded for eye, liver and testis than with brain 
(without cerebellum) and cerebellum (cb). (b) Quantitative real time PCR to 
determine levels of Glialcam, Mlc1 and Clcn2 mRNA in the cerebellum of 
different mouse models. Primers were chosen to amplify regions that were not 
deleted in corresponding KO mice. Bars, relative expression level compared to 
WT sibling; error bars, standard deviation (n≥2). (c) Comparison of ClC-2, 
GialCAM and MLC1 protein levels in cerebellum and (d) remainder of brain of 
WT, Glialcam-/-, Glialcamdn/dn, Mlc1-/- and Clcn2-/- mice by Western blots of 
membrane fractions from 10 week-old mice. (c) and (d) show Western blots 
representative for three independent experiments. Actin served as loading 
control.  All full size blots can be found in Supplementary Fig. 2. 
 
Figure 2 | Altered localization of ClC-2 GlialCAM and MLC1 in BG of 
Glialcam and Mlc1 mouse models. (a) Immunohistochemical (IHC) staining of 
ClC-2, GlialCAM and MLC1 in the molecular layer of the cerebellum. Co-
staining for the astrocytic cytoskeletal protein GFAP (red) visualizes BG 
processes. Somata of BG are located in the Purkinje cell layer (pcl). Arrows with 
filled heads point to staining along BG processes, arrows with open heads point 
to labeled BG somata. Staining respective KO sections controls the specificity 
of antibodies. Note that ClC-2 staining in the Purkinje cell layer of Clcn2-/- mice 
results from non-specific nuclear staining by the ClC-2 antibody. Scale bar = 50 
µm. (b) IHC staining of ClC-2, GlialCAM and MLC1 in BG somata of the 
cerebellar Purkinje cell layer. Sections were co-stained for the astrocyte marker 
protein S100ß (red) which localizes to the cytoplasm of BG. Nuclei were stained 
with DAPI. Scale bar = 5 µm. For each genotype / antibody combination, two 
brain sections each of at least 3 different mice were analysed. 
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Figure 3 | ClC-2 MLC1 and GlialCAM but not aquaporin-4 and Kir4.1 are 
mislocalized along blood vessels in Glialcam and Mlc1 mouse models. (a) 
Immunofluorescent staining of ClC-2, GlialCAM and MLC1 along blood vessels 
of the hippocampus in mice of different genotypes.  Sections were co-stained 
for perlecan (heparan-sulfate-proteoglycan) a marker for endothelial cells. (b) 
Immunofluorescent staining of Aquaporin-4 (AQP4) and Kir4.1 along blood 
vessels of the hippocampus. Section were co-stained with the astrocyte marker 
GFAP which labels astrocytic endfeet contacting blood vessels. Scale bar = 5 
µm. For each genotype and antibody combination, two brain sections each of at 
least 2 different mice were analysed. 
 
Figure 4 | Altered localization of ClC-2 GlialCAM and MLC1 in OLs of 
Glialcam and Mlc1 mouse models. Immunohistochemical staining of OLs in 
fibre tracts of the cerebellum. The cytoplasm of OLs was stained with an 
antibody against APC (adenomatous polyposis coli) protein. This co-labelling 
revealed considerable amounts of GlialCAM and MLC1 in cells adjacent to OLs 
(bona fide astrocytes), as particularly evident in Glialcamdn/dn mice. The faint 
punctate staining of nuclei with the MLC1 and ClC-2 antibodies is unspecific as 
revealed by Mlc1-/- and Clcn2-/- sections, respectively. Note that GlialCAM and 
MLC1 labelling is unchanged in Clcn2-/- mice. Dotted lines mark the location of 
nuclei within OLs. Scale bar = 5 µm. For each genotype / antibody combination, 
at least 2 brain sections each of at least 3 different mice were analysed. 
 
Figure 5 | Enrichment of ClC-2 GlialCAM and MLC1 at cell-cell contacts 
requires expression of GlialCAM in both neighbouring cells. HeLa cells 
were transfected with different combinations of Clcn2, Glialcam and Mlc1 
cDNAs (untagged or haemagglutinin (HA)-tagged). Differentially transfected 
cells were plated onto coverslips and processed for immunofluorescent staining. 
Individual channel images are displayed in the first three columns, merged 
images are shown in the fourth column (from left to right). Labels in the lower 
left corner of each panel indicate the overexpressed protein that was stained 
with specific antibodies. cDNAs transfected into cells are indicated to the left of 
each row; in the fourth row cells are labeled with “*” and “#” according to the 
cDNA combination they were transfected with. Arrows with filled heads point to 
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cell-cell contacts with protein enrichment, arrows with open heads to contacts 
without protein enrichment. Scale bar = 20 µm; C2 = ClC-2; GC = GlialCAM; M1 
= MLC1. Images shown are representative of at least four images from at least 
two independent experiments. 
 
Figure 6 | ClC-2 currents in Bergmann glia. (a-j) Current tracings from 
voltage-clamped BG were averaged for the different mouse models analysed 
(aged 3-4 weeks). ClC-2 currents were elicited with a voltage pulse protocol. As 
labeled, measurements were done in either: isotonic (iso), hypotonic (hypo), or 
hypertonic (hyper) bath conditions. Cells were first patched in aCSF and then 
superfused with an NMDG+-based ‘isotonic’ solution containing carbenoxolone 
to measure ClC-2 currents. Sometimes, this was followed by superfusion with 
either a hypotonic or hypertonic bath solution for additional measurements. The 
number of cells averaged were: WT, iso [9]; WT, hypo [3]; Clcn2-/-, iso [7]; 
Glialcam-/-, iso [15], Glialcam-/-, hyper [5]; Mlc1-/-, iso [9]; Mlc1-/-, hyper [3], 
Glialcamdn/dn, iso [11]; Glialcamdn/dn, hyper [4]. Note that some experiments 
using shorter and longer pulse protocols were not included for averaging traces 
shown here but were included for statistical analysis. Traces are scaled 
uniformly. (k) Individual membrane capacitance values of BG from different 
genotypes.  Horizontal and vertical bars represent mean and SEM, respectively.  
P values between WT and the various mouse models using the Mann-Whitney 
test: * p≤0.05, *** p≤0.001, **** p≤0.0001. (l, m) Current densities (amplitudes 
normalized to capacitance) as a function of voltage measured in isotonic bath 
conditions at 0.25 s (l) or 1.5 s (m) after the beginning of the voltage pulse. 
Plotted values are mean ± SEM. The total number of cells in (l,m) is given in 
panel (l).  Legend symbols in (l) apply also to symbols in (m). 
 
Figure 7 | ClC-2 currents in OLs. (a, c, d, f, h, j) Current tracings from 
voltage-clamped OLs of the corpus callosum in isotonic bath solutions were 
averaged for the different mouse models analysed. Currents were elicited in the 
same way as described in Fig 5. The number of cells used for averaging traces 
were WT [22], Clcn2-/- [9], Glialcam-/- [11], Mlc1-/- [17], and Glialcamdn/dn [9], 
Glialcam+/- [12]. (b, e, g, i, k) The average current from Clcn2-/- cells was 
subtracted from the average current from respective mouse models to obtain 
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the ‘subtracted’ current which is due to ClC-2 expression. (l) Confocal scans of 
tissue sections for selected mouse models where OLs were dialyzed with 
biocytin through the patch pipette. Scale bar is 100µm. (m) Individual 
membrane capacitance values of OLs from different genotypes.  Horizontal and 
vertical bars represent mean and SEM, respectively.  Reported p values were 
calculated between WT and the various mouse models using the Mann-Whitney 
test. * p≤0.05, ** p≤0.01. (n) Current densities (amplitude normalized to 
capacitance)  measured at the end of a 1.5s voltage pulse as a function of 
clamp voltage plotted as mean ± SEM. 
 
Figure 8 | Myelin vacuolization in Glialcam and Mlc1 mouse models. (a) 
H&E stainings of sagittal paraffin sections of cerebellum of 8, 16 and 52 week 
old mice. (b) Ultrastructural analyses of myelin vacuolization. Myelin 
vacuolization at different magnifications. asterisk = myelin vacuole; arrow = 
aberrant myelin sheet inside vacuole; a = axon; o = oligodendrocyte; bv = blood 
vessel. Scale bars: upper row = 5µm, middle row = 2 µm, bottom row = 1 µm. 
(c) H&E staining of cerebellum of 8 week old Clcn2-/-, Glialcam-/- double mutant 
mice. (d) H&E staining of cerebellum of 17 week-old Clcn2hyp/hyp, Glialcam-/- 
double mutant mice. Scale bar in a, c, d= 400 µm. For each genotype and age 
2 animals (≥4 sections each) were analysed. 
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Table 1. Summary of Major Phenotypes in Mouse Models of Leukodystrophy 
 
 WT Clcn2-/- Glialcam-/- Mlc1-/- Glialcamdn/dn 
Myelin vacuolization1  - ●●● ●● ●● ●● 
Protein expression2 :      
     ClC-2 ctrl -    
     GlialCAM ctrl ↔ - ↔ ↔ 
     MLC1 ctrl   -  
Localization along BG processes3 :      
     ClC-2 + - - - - 
     GlialCAM + + - - - 
     MLC1 + + - - - 
Cl- currents of BG :      
     Rectification4 + n/a + + + 
     Current density5 ctrl n/a    
     Apparent inactivation + n/a - - - 
Membrane capacitance6 ctrl     
Clustering around OL somata7 :      
     ClC-2 + - - - - 
     GlialCAM + + - - - 
     MLC1 + + - - - 
Cl- currents of OL :      
     Rectification4 - n/a + + + 
     Current density8 ctrl n/a    
Membrane capacitance6 ctrl     
Localization along blood vessels :      
     ClC-2 + -    
     GlialCAM + ↔ -   
     MLC1 + ↔  -  
1Degree of vacuolization scored in the cerebellum. Glialcam+/dn mice displayed weakest 
vacuolization (●). Clcn2-/-Glialcam-/- mice displayed strongest vacuolization (●●●●). 
2Changes in protein expression in the cerebellum of the different mouse models compared to 
WT.  
3Scored for the presence and absence of protein located along Bergmann glia processes in 
different mouse models. 
4 Activation by hyperpolarization (inward rectifying). 
5Measured at 0.25s from the start of the voltage pulse.  Changes compared to WT. 
6Changes compared to WT. 
7Scored for the presence and absence of protein clustered around the somata of OLs in 
different mouse models. 
8Measured at the end of the voltage pulse (1.5s).  Changes compared to WT. 
Ctrl, control; n/a, not applicable; ↔ no change,  increase,  decrease compared to WT;    
+ present; - absent; BG, Bergmann glia; OL, oligodendrocytes 
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